Published 16 hours ago • loading... • Updated 16 hours ago

An already-ailing alcohol industry might have a new problem: GLP-1s

A study found that people using GLP-1s spent 30 percent less on alcohol while they were out at a bar, pub or restaurant.

1 Articles

lehighvalleylive

Lean Left

An already-ailing alcohol industry might have a new problem: GLP-1s

A study found that people using GLP-1s spent 30 percent less on alcohol while they were out at a bar, pub or restaurant.

16 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left1Leaning Right0Center0Last Updated16 hours agoBias Distribution

100% Left

Bias Distribution

100% of the sources lean Left

100% Left

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

lehighvalleylive broke the news 16 hours ago on Friday, October 30, 2026.

Sources are mostly out of (0)

An already-ailing alcohol industry might have a new problem: GLP-1s

1 Articles

1 Articles

An already-ailing alcohol industry might have a new problem: GLP-1s

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Doctor warns of potential long-term side effects from GLP-1 weight loss drugs

West Pharmaceutical: Q3 Earnings Snapshot

Avvisa Approves 5 New Weight Loss and Diabetes Pens; See Which Ones

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

Surprising Glasgow Figures Revealed for Ozempic and Mounjaro Prescriptions

Australia Has Highest Rates of Anorexia and Bulimia Globally

Similar News Topics

Similar News Topics

More stories like this

Doctor warns of potential long-term side effects from GLP-1 weight loss drugs

West Pharmaceutical: Q3 Earnings Snapshot

Avvisa Approves 5 New Weight Loss and Diabetes Pens; See Which Ones

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

Surprising Glasgow Figures Revealed for Ozempic and Mounjaro Prescriptions

Australia Has Highest Rates of Anorexia and Bulimia Globally

An already-ailing alcohol industry might have a new problem: GLP-1s

1 Articles

1 Articles

An already-ailing alcohol industry might have a new problem: GLP-1s

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Doctor warns of potential long-term side effects from GLP-1 weight loss drugs

West Pharmaceutical: Q3 Earnings Snapshot

Avvisa Approves 5 New Weight Loss and Diabetes Pens; See Which Ones

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

Surprising Glasgow Figures Revealed for Ozempic and Mounjaro Prescriptions

Australia Has Highest Rates of Anorexia and Bulimia Globally

Similar News Topics

Similar News Topics

More stories like this

Doctor warns of potential long-term side effects from GLP-1 weight loss drugs

West Pharmaceutical: Q3 Earnings Snapshot

Avvisa Approves 5 New Weight Loss and Diabetes Pens; See Which Ones

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

Surprising Glasgow Figures Revealed for Ozempic and Mounjaro Prescriptions

Australia Has Highest Rates of Anorexia and Bulimia Globally

Bias Distribution

Factuality